Cite

HARVARD Citation

    Shaikh, S. et al. (n.d.). 435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma. Journal for immunotherapy of cancer. p. A265. [Online]. 
  
Back to record